Market News
Stay updated with the latest market trends, earnings, and economic indicators.
BPCL Boosts Petrochemical Business Footprint | Shilpa Medicare Partners Orion for Nivolumab | Top Buzzing Stocks Today - Equitymaster
BPCL Boosts Petrochemical Business Footprint | Shilpa Medicare Partners Orion for Nivolumab | Top Buzzing Stocks TodayEquitymaster
Shilpa Medicare jumps 6% to hit 52-week high; check what's fuelling gains
Shilpa Medicare has announced that its wholly owned subsidiary, Shilpa Biologicals, has entered into a co-development and supply agreement with Orion Corporation
Shilpa Medicare shares gain 5% after arm partners with Orion Corp for cancer treatment drug
Shilpa Medicare shares rose over 5% after its subsidiary partnered with Orion to co-develop and supply a nivolumab biosimilar for Europe. Orion will market the drug, while the Shilpa Medicare arm handles manufacturing. The deal aims to expand access to affordable cancer therapy.
Shilpa Medicare jumps as subsidiary signs biosimilar pact with Finland's Orion
Shilpa Medicare jumped 5.40% to Rs 604.55 after its wholly owned subsidiary, Shilpa Biologicals, signed a co-development and supply agreement with Finland-based Orion Corporation.
Shilpa Biologicals commissions Antibody-Drug Conjugate (ADC) GMP manufacturing facility
Shilpa Biologicals, a material subsidiary of Shilpa Medicare, announced the commissioning of a state-of-the-art Antibody-Drug Conjugate (ADC) GMP manufacturing facility, purpose-built and designed to meet global regulatory approval standards including US FDA, EMA, and other major health authority requirements. The facility is fully operational, with GMP qualification protocols now actively underway, placing Shilpa on a clear path to commercial readiness.
IFCI Ltd leads losers in 'A' group
IDBI Bank Ltd, Inox India Ltd, Shilpa Medicare Ltd and Shaily Engineering Plastics Ltd are among the other losers in the BSE's 'A' group today, 18 June 2026.
Aurobindo Pharma Ltd leads losers in 'A' group
Ola Electric Mobility Ltd, Aster DM Healthcare Ltd, Data Patterns (India) Ltd and Shilpa Medicare Ltd are among the other losers in the BSE's 'A' group today, 15 June 2026.
Shilpa Biocare to acquire 30.4% stake in Barcelona-based Gate2Brain
Shilpa Medicare announced that its wholly owned subsidiary, Shilpa Biocare intends to make a strategic equity partnership of 30.4% in Gate2Brain. The investment of Euro 7 million includes cash infusion of Euro 0.5 million, equity for services Euro 5.5 million and Euro 1 million for development of project.
Shilpa Medicare to acquire 30.4% stake in Spain's Gate2Brain with €7 million investment
The global glioblastoma treatment market is estimated at approximately $3 billion in 2025 and is projected to exceed $6 billion by 2035. The pediatric brain tumour market is estimated at around $1.5 billion, while the market for DIPG therapies is expected to reach nearly $1.2 billion by 2035.
Shilpa Medicare consolidated net profit rises 642.87% in the March 2026 quarter
Sales rise 32.09% to Rs 436.99 crore
Shilpa Medicare Q4 results: Shares gain on sharp profit growth, exceptional gains boost earnings
Shilpa Medicare Q4FY26 profit surged to ₹108 crore on higher revenue and exceptional gains, FY26 earnings improved, dividend proposed. The company approved shifting its registered office from Karnataka to Maharashtra, subject to regulatory and shareholder approvals.
NCLT approves Shilpa Therapeutics’ amalgamation with Shilpa Medicare
Shares of Shilpa Medicare Ltd ended at ₹328.00, up by ₹12.15, or 3.85%, on the BSE.